Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its first-quarter financial results before the markets opened on Tuesday.

Why Regeneron Earnings Are Taking a Backseat to Its COVID-19 Update

Regeneron (REGN) beats on Q1 earnings and sales on solid performance of ophthalmology drug, Eylea; asthma drug, Dupixent; and oncology drug, Libtayo.

Regeneron's (REGN) Q1 Earnings & Sales Surpass Estimates

Regeneron earnings and sales topped first-quarter estimates. REGN stock was not yet active, but has been a big winner over the past few months.

Regeneron Earnings Easily Beat Views; Biotech Giant Stock Near Highs

Regeneron Pharmaceuticals Inc. REGN, +3.10% reported Tuesday profit and revenue that rose above expectations, and said it plans to begin human studies of its REGN-COV2 antibody "cocktail" treatment for the COVID-19 virus in June, and is working to scale-up manufacturing.

Regeneron earnings beat expectations, plans to begin human studies of COVID-19 treatment in June

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regeneron (REGN) Reports Next Week: Wall Street Expects Earnings Growth

Gilead Sciences

Vir Biotechnology

While the stock markets have declined this year due to the spread of the novel coronavirus, stocks of pharma companies developing treatments and vaccines for the highly contagious viral infection have fared quite well.

Best Coronavirus Treatment Stock: Gilead, Regeneron, Or Vir?

Sanofi

The companies shared good news about lung cancer patients treated with Libtayo, and bad news about a potential treatment for COVID-19.

Positive Cancer Trial Results Offset a COVID-19 Flop for Regeneron and Sanofi

Biogen

These are the health care stocks with the best value, fastest growth, and most momentum for May.

Top Health Care Stocks for May 2020

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) is collaborating with Sanofi SA (EPA: SAN) to test Kevzara (arthritis drug) as a potential treatment for COVID-19.

Regeneron and Sanofi’s arthritis drug shows no benefit in non-critical COVID-19 patients

The companies are halting clinical studies of the drug in those with severe cases of COVID-19 and focusing only on critical patients.

Regeneron, Sanofi Say Kevzara Will Now Only Be Tested in Sickest COVID-19 Patients

Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading lower on Monday. The company's trial of arthritis drug Kevzara with Sanofi (NYSE: SNY) showed potential for treating the sickest coronavirus patients, but showed less benefit in patients with less-advanced disease.

Why Regeneron's Stock Is Trading Lower Today

Amgen

Incyte

Vertex Pharmaceuticals

Focus on Coronavirus Treatments to Boost Biotech Stocks

Kinross Gold

Meet Group

SpartanNash

Vipshop Hlds

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

5 Stocks Trading Near  52-Week High That Can Scale Higher

Shares of Regeneron Pharmaceuticals Inc. REGN, +0.12% were down 0.9% and Sanofi's SNY, +3.06% stock gained 2.6% in premarket trading on Monday after the companies reported less-than-promising results from a mid-stage trial testing their rheumatoid arthritis drug Kevzara in COVID-19 patients.

Regeneron, Sanofi say Kevzara will only be tested in sickest COVID-19 patients

The drug, Kevzara, inhibits a pathway thought to contribute to the lung inflammation in patients with the most severe forms of Covid-19.

Regeneron, Sanofi arthritis drug shows benefit for sickest coronavirus patients, but not for less- advanced cases

Amazon

Citrix Systems

Newmont Mining

Netflix

NortonLifeLock

Southwestern Energy

The S&P 500 has rallied hard off its March lows, but the index remains down 12.9% year-to-date overall.

7 Best-Performing Stocks Of 2020: Buy, Sell Or Hold?

The global economic slowdown hammered many of their peers, but swift decision-making has helped lift these two biotechs' shares much higher.

While Big Pharma Tanked, Gilead Sciences and Regeneron Soared

CRISPR Therapeutics

Galapagos

Neurocrine Biosciences

Acceleron Pharma

Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.

7 Beautiful Biotech Stocks to Buy Here

Certain patents covering a biotech giant's multi-billion dollar biologic are set to expire starting this year. Does this mean an end for its stellar growth?

Does Regeneron Pharmaceuticals’ Winning Streak Signal Irrational Exuberance?

ProShares Long Online/Short Stores ETF

Luminex

Teladoc

What if somehow you knew what the Senators had heard and you had a chance the next day to call your broker and place a few orders for just the right stocks?

4 Stocks That Performed Very Well Following The 1/23 Senate Classified Intelligence Briefing.

Advanced Micro Devices

Digital Realty Trust

Equinix

Jack Henry & Associates

Eli Lilly

MSCI

SBA Communications

Despite a year-to date drop of -13.9%, the S&P 500 could still be overpriced by 35%. If the S&P 500 is overvalued, component stocks must be.

10 S&P 500 Stocks That Are Still Overvalued By Discounted Cash Flow

The FDA accepts Regeneron's (REGN) BLA for REGN-EB3 under a priority review to treat the deadly Ebola virus infection. A verdict is pending on Oct 25, 2020.

Regeneron's BLA for Ebola Vaccine Gets FDA's Priority Review

Masimo

Zoom Video

Here we discuss five stocks poised to gain maximum benefits from the staggered reopening of U.S. economy, per the latest guidelines.

Trump Plans Steady Economic Reboot: 5 Coronavirus-Proof Bets

Moderna

Vaxart

The whole world has pinned hopes on pharmaceutical and biotech companies to create drugs and vaccine to help combat COVID-19.

Buy 5 Top Medical Stocks on Coronavirus  Drug Trial Results

Regeneron has solid cash flow and a strong balance sheet. Oh and Regeneron stock is flirting with a major breakout.

News for Regeneron Pharmaceuticals Stock (REGN)